Latest revision as of 13:00, 1 February 2024

Back to Top

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main TNBC page for regimens that include active anticancer treatment.

Adjuvant therapy

Observation

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Lluch et al. 2019 (GEICAM/2003-11; CIBOMA/2004-01)	2006-2011	Phase 3 (C)	Capecitabine	Did not meet primary endpoint of DFS
Wang et al. 2021 (SYSUCC-001)	2010-2016	Phase 3 (C)	Capecitabine	Inferior DFS

Note: No further systemic treatment.

Preceding treatment

Surgery

References

GEICAM/2003-11; CIBOMA/2004-01: Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020 Jan 20;38(3):203-213. Epub 2019 Dec 5. Erratum in: J Clin Oncol. 2020 Mar 10;38(8):847. link to original article link to PMC article PubMed NCT00130533
SYSUCC-001: Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021 Jan 5;325(1):50-58. link to original article link to PMC article PubMed NCT01112826

Placebo

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Schmid et al. 2020 (KEYNOTE-522)	2017-03 to 2018-09	Phase 3 (C)	Pembrolizumab	Inferior EFS¹

¹Reported efficacy is based on the 2022 update.
No active antineoplastic treatment within the study design.

Preceding treatment

Surgery

References

KEYNOTE-522: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. link to original article PubMed NCT03036488
1. Update: Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. link to original article PubMed

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Breast cancer, triple negative|main TNBC page]] for current regimens.
+The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Breast cancer, triple negative|main TNBC page]] for regimens that include active anticancer treatment.
 {{TOC limit|limit=3}}
@@ Line 22: / Line 22: @@
 |[[Breast_cancer,_triple_negative#Capecitabine_monotherapy|Capecitabine]]
 | style="background-color:#ffffbf" |Did not meet primary endpoint of DFS
-|-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671866/ Nasr et al. 2015]
-|2008-2014
-|style="background-color:#1a9851" |Phase 3 (C)
-|[[#Cyclophosphamide_.26_Methotrexate_.28CM.29_888|CM]]
-| style="background-color:#fc8d59" |Seems to have inferior OS
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729589/ Wang et al. 2021 (SYSUCC-001)]
@@ Line 42: / Line 36: @@
 </div></div>
 ===References===
-# Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015 Nov;3(19):284. [https://doi.org/10.3978/j.issn.2305-5839.2015.11.14 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671866/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26697444/ PubMed]
 # '''GEICAM/2003-11; CIBOMA/2004-01:''' Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020 Jan 20;38(3):203-213. Epub 2019 Dec 5. Erratum in: J Clin Oncol. 2020 Mar 10;38(8):847. [https://doi.org/10.1200/jco.19.00904 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6968797/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31804894/ PubMed] [https://clinicaltrials.gov/study/NCT00130533 NCT00130533]
 # '''SYSUCC-001:''' Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021 Jan 5;325(1):50-58. [https://doi.org/10.1001/jama.2020.23370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729589/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33300950/ PubMed] [https://clinicaltrials.gov/study/NCT01112826 NCT01112826]
@@ Line 70: / Line 63: @@
 </div></div>
 ===References===
-# '''KEYNOTE-522:''' Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. [https://doi.org/10.1056/nejmoa1910549 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32101663/ PubMed] [https://clinicaltrials.gov/study/NCT03036488 NCT03036488]
+# '''KEYNOTE-522:''' Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. [https://doi.org/10.1056/nejmoa1910549 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32101663/ PubMed] [https://clinicaltrials.gov/study/NCT03036488 NCT03036488]
 ##'''Update:''' Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. [https://doi.org/10.1056/nejmoa2112651 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35139274/ PubMed]
 [[Category:Breast cancer regimens]]
 [[Category:Null regimens]]
-[[Category:Histology-specific pages]]
+[[Category:Biomarker-specific pages]]
 [[Category:Malignant breast neoplasm]]

Difference between revisions of "Breast cancer, triple negative - null regimens"

Latest revision as of 13:00, 1 February 2024

Contents

Adjuvant therapy

Observation

Regimen

Preceding treatment

References

Placebo

Regimen

Preceding treatment

References

Navigation menu

Search